Connect with us

News

MGC Pharma gets go-ahead for trial in Covid-19 patients

Published

on

The study will test the effectiveness of CimetrATM of patients who are hospitalised with COVID-19

Cannabis giant MGC Pharmaceuticals has received approval for a phase three clinical trial in patients with Covid-19.

The European based bio-pharma company has been given the go-head to evaluate the efficacy and safety of CimetrATM as a treatment for moderate hospitalised patients diagnosed with COVID-19

The company received Ethics Committee approval from Rambam Health Care Campus and Nazareth Hospital EMMS in Israel, to conduct a Phase III Clinical Trial.

This is now scheduled to commence in early April, and will provide essential data to plan for the potential future registration of CimetrATM as a drug.

CimetrATM is designed to target viral infections with inflammatory complications and was successfully evaluated on COVID-19 patients in a double-blind placebo controlled, Phase II clinical trial.

Under the move to a Phase III clinical trial, the classification of the product has changed from a food supplement to an IMP. As a result, the product name under the Trial has changed from ArtemiCTM to CimetrATM

In February, MGC which specialises in the production and development of phyto-derived medicines, became the first cannabis company to list on the London Stock Exchange and is fully funded to complete the trial after raising £6.5million.

The trial is designed to test CimetrATM on moderate hospitalised patients infected with COVID-19 for safety and efficacy, with the purpose of treating the pathophysiological repercussions of infection with the coronavirus.

Researchers will assess the efficacy and safety of the natural anti-inflammatory formulation CimetrA™, based on Curcumin and Boswellia Serrata as Anti-inflammatory agents with the supporting ingredient Artemisinin as an  Antiseptic peroxide bridge, which are all well-known natural active ingredients with immunomodulatory properties.

A total of 252 patients infected with COVID-19, across clinical sites in Israel and Brazil, will be evaluated, over a period of 28 days per patient.

Interim results are expected to be published in June 2021, before the trial concludes in September and full results become available during October. 

Roby Zomer, co-founder and managing director of MGC Pharma, commented: “This is a very significant milestone for the company being the first Phase III clinical trial of CimetrATM

ArtemiCTM has already proven to be a very successful product for the Company, and we look forward to replicating this with CimetrATM as an IMP and improve outcomes for COVID-19 patients.”

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.